SCHEMBL4202199

SCHEMBL4202199

CCOC(=O)N1CCC(c2cc(Cl)n3nccc3n2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 4/20 0.55
HPGD P15428 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 3/20 0.50
NOS2 P35228 5/20 0.47
NOS1 P29475 4/20 0.47
TRPC3 Q13507 3/20 0.45
TRPC7 Q9HCX4 3/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 2/20 0.44
NOS3 P29474 2/20 0.43
CHEK1 O14757 1/20 0.43
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
GAA P10253 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953174 0.86 TRPC3 (0.52) ALDH1A1KDM4EHPGDNPSR1HSD17B10
SCHEMBL2679455 0.86 GPR119 (0.48) ALDH1A1KDM4EHPGDNPSR1HSD17B10
SCHEMBL594986 0.83 PDE10A (0.47) ALDH1A1KDM4EHPGDNPSR1HSD17B10
SCHEMBL594178 0.80 GPR119 (0.45) ALDH1A1KDM4EHPGDNPSR1HSD17B10
SCHEMBL4217731 0.80 DPP4 (0.52) ALDH1A1KDM4EHPGDNPSR1HSD17B10
SCHEMBL14413461 0.79 PDE10A (0.44) CHEK1PDE10A
SCHEMBL10236625 0.76 PDE10A (0.43) ALDH1A1KDM4EHPGDHTTLMNA
SCHEMBL583894 0.76 PDE10A (0.43) ALDH1A1KDM4EHPGDHTTLMNA
SCHEMBL12953214 0.76 JAK2 (0.45) NPSR1TRPC3TRPC7MEN1KMT2A
SCHEMBL12953168 0.75 SMN1; SMN2 (0.53) ALDH1A1KDM4EHPGDNPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
EP-1970373-A1 ALICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182140-A1 Alicyclic Heterocyclic Compound CCR4, CCR1, HRH4 ALDH1A1 1767/4885KDM4E 657/4885HPGD 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.